Table 2.
Demographics, treatment, and medical characteristics of the study participants. Information was reported by participants, except treatment information which was obtained from medical records.
| Variable | Onboarded cohort (N=120) n (%) |
Analysis cohort (N = 104) n (%) |
Completer cohort (N = 81) n (%) |
|---|---|---|---|
| Demographics from participant reports | |||
| Gender | |||
| Female | 89 (74%) | 76 (73%) | 57 (70%) |
| Male | 27 (23%) | 24 (23%) | 21 (26%) |
| Other | 4 (3%) | 4 (4%) | 3 (4%) |
| Age (years) | |||
| < 30 | 47 (39%) | 43 (41%) | 31 (38%) |
| 30 – 39 | 34 (28%) | 28 (27%) | 22 (27%) |
| 40+ | 39 (33%) | 33 (32%) | 28 (35%) |
| Are you Hispanic/Latino? | |||
| Yes | 1 (1%) | 1 (1%) | 1 (1%) |
| No | 119 (99%) | 103 (99%) | 80 (99%) |
| Race | |||
| Asian | 2 (1.5%) | 2 (2%) | 1 (1%) |
| Black or African American | 2 (1.5%) | 2 (2%) | 2 (3%) |
| Native Hawaiian or other Pacific Islander | 1 (1%) | 1 (1%) | 0 (0%) |
| White | 113 (94%) | 97 (93%) | 76 (94%) |
| Other | 1 (1%) | 1 (1%) | 1 (1%) |
| Multi-racial | 1 (1%) | 1 (1%) | 1 (1%) |
| Treatment-related data from medical records | |||
| CBI treatment duration | |||
| 1 – 3 months | 6 (5%) | 4 (4%) | 2 (3%) |
| 4 – 6 months | 16 (13%) | 14 (13%) | 10 (12%) |
| 7 – 9 months | 10 (8%) | 10 (10%) | 9 (11%) |
| 10 – 12 months | 7 (6%) | 5 (5%) | 4 (5%) |
| 1 – 2 years | 34 (28%) | 31 (30%) | 26 (32%) |
| Over 2 years | 45 (38%) | 38 (36%) | 29 (36%) |
| Unknown | 2 (2%) | 2 (2%) | 1 (1%) |
| Treated elsewhere previously | |||
| Yes | 34 (28%) | 23 (22%) | 18 (22%) |
| No | 83 (69%) | 78 (75%) | 61 (75%) |
| Unknown | 3 (3%) | 3 (3%) | 2 (3%) |
| Medical data from participant reports | |||
| Psychiatric medication usage | |||
| Yes – medications meeting exclusion criteria | 5 (4%) | n/a | n/a |
| Yes – only medications not meeting exclusion criteria (1) | 86 (72%) | 76 (73%) | 55 (68%) |
| No | 29 (24%) | 28 (27%) | 26 (32%) |
| Do you currently have any of the following health conditions? (2) | |||
| Asthma | 18 (15%) | 16 (15%) | 11 (14%) |
| Cardiovascular disease | 1 (1%) | 0 (0%) | 0 (0%) |
| Diabetes | 4 (3%) | 3 (3%) | 3 (4%) |
| Hypertension | 16 (13%) | 12 (12%) | 11 (14%) |
| Obesity | 28 (23%) | 20 (19%) | 16 (20%) |
| Other not listed here | 28 (23%) | 20 (19%) | 16 (20%) |
| None of the above | 60 (50%) | 55 (53%) | 42 (51%) |
(1) 10 most prevalent medications: fluoxetine (n=21), sertraline (n=18), escitalopram (n=16), buproprion (n=14), lamotrigine (n=8), buspirone (n=7), lisdexamfetamine (n=6), methylphenidate (n=6), venlafaxine (n=5), duloxetine (n=5).
(2) More than one category may apply, so the percentages may sum to more than 100%.